By:
On:
In: Insurance

The following is a summary of the information covered during the Emgality Q&A LIVE on September 24, 2021. Emgality Safety FDA Adverse Events Reporting System Reports on a particular drug or biologic do not mean that the drug or biologic caused the adverse event. FAERS data by themselves are notRead More →

By:
On:
In: Calcitonin Gene-Related Peptide, Case Studies, CGRP, Emgality, Preventives, Treatments
With: 0 Comments

CGRP has an important pathophysiological role in cluster headache. Chronic cluster headache patients with insufficient response to other preventive treatments have been receiving individual off-label treatment attempts with CGRP antibodies.Read More →